Annual Meeting Achived Material

23rd Annual PPAG Meeting Agenda and Learning Objectives

 

 

 

2014 Speaker Presentation With Objectives and Schedule

 

Wednesday, April 30, 2014

 

Iron Chelators

0180-0000-14-300-L01-P

​Program Type: Knowledge-based

Clinical Pearl

Wednesday, April 30, 2014

10:00-10:20 am

 

Session Handout: www.ppag.org/23AM/mahto.pdf

 

Jaimi Mahto, PharmD

Clinical Pharmacist

University Of New Mexico Childrens Hospital, Albuquerque, New Mexico

 

At the end of this session, participants will be able to:

1.        Role of Iron in our body.

2.        Treatment of Iron overload, Role of Iron chelators.

3.        Recent developments in Iron Chelation therapy.

 

 

The Facts of Factor VIII

0180-0000-14-301-L01-P

Program Type: Knowledge-based

Clinical Pearl

Wednesday, April 30, 2014

10:20-10:40 am

 

Session Handout: www.ppag.org/23AM/troutman.pdf

 

Kailey Troutman, PharmD

PGY1

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

 

At the end of this session, participants will be able to:

1.        Review the pathophysiology of Hemophilia A

2.        Discuss the current recommendations for management of hemophilia bleeding episodes

3.        Identify the development of Factor VIII products used in hemophilia A

4.        Recognize appropriate dosing and administration of Factor VIII

 

 

Update on MABs and NIBs

0180-0000-14-302-L01-P

Program Type: Knowledge-based

Clinical Pearl

Wednesday, April 30, 2014

10:40-11:00 am

 

Session Handout: www.ppag.org/23AM/parsons_pearl.pdf

 

Kerry Parsons, PharmD, BCOP

Clinical Pharmacist, Oncology

Children's of Alabama, Birmingham, Alabama

 

At the end of this session, participants will be able to:

1. Describe pharmacology principles of monoclonal antibodies (MABs) relevant to pediatric cancer.

2. Describe pharmacology principles of tyrosine kinase inhibitors (NIBs) relevant to pediatric cancer.

3. Discuss major toxicities of MABs and NIBs relevant to developing a monitoring and supportive care regimen.

 

 

Pediatric Oncology: An Introduction to the Fundamental Building Blocks

0180-0000-14-303-L01-P

Program Type: Knowledge-based

General Session

Wednesday, April 30, 2014

11:00-11:30 am

 

Session Handout: www.ppag.org/23AM/koontz.pdf

 

Susannah Koontz, PharmD, BCOP

Oncology Consultant Pharmacist

Koontz Oncology Consulting LLC, Houston, Texas

 

At the end of this session, participants will be able to:

1.        Identify the most common cancers that occur in children

2.        Describe the epidemiology and biology of commonly occurring cancers in children

3.        List treatment modalities used in the management of pediatric malignancies

 

 

Tumor Lysis Syndrome

0180-0000-14-304-L01-P

Program Type: Knowledge-based

General Session

Wednesday, April 30, 2014

11:30-12:00 pm

 

Session Handout: www.ppag.org/23AM/dabb.pdf

 

Alix Dabb, PharmD

Clinical Pharmacy Specialist, Oncology

The Johns Hopkins Hospital, Baltimore, Maryland

 

At the end of this session, participants will be able to:

1.        Describe the pathophysiology of tumor lysis syndrome

2.        Identify risk factors for developing tumor lysis syndrome

3.        List the pharmacologic agents that may be utilized for prophylaxis and treatment of tumor lysis syndrome

 

 

Antiviral Prophylaxis: How NOT to Go Viral

0180-0000-14-305-L01-P

Program Type: Knowledge-based

Acute Care Track

Wednesday, April 30, 2014

1:30-2:00 pm

 

Session Handout: www.ppag.org/23AM/bernhardt.pdf

 

M. Brooke Bernhardt, PharmD, MS, BCOP

Clinical Pharmacy Specialist, Hematology and Oncology

Texas Children's Hospital, Houston, Texas

 

At the end of this session, participants will be able to:

1.        Recognize risk factors for viral infections in children with cancer

2.        Examine the data on antiviral prophylaxis in children with cancer

3.        Recommend potential guidelines for the use of antiviral prophylaxis in children wtih cancer

 

 

Combination Anti-fungal Therapy

0180-0000-14-306-L01-P

Program Type: Knowledge-based

Acute Care Track

Wednesday, April 30, 2014

2:00-2:30 pm

 

Session Handout: www.ppag.org/23AM/thackray.pdf

 

Jennifer Thackray, PharmD, BCPS

Clinical Pharmacy Specialist, Oncology

Memorial Sloan Kettering Cancer Center, New York, New York

 

At the end of this session, participants will be able to:

1.        Describe risk factors and common organisms responsible for invasive fungal infections (IFIs) in the immunocompromised patient

2.        Identify clinical signs, symptoms and laboratory abnormalities suggestive of an IFI

3.        Summarize current treatment recommendations for the management of IFIs

4.        Evaluate novel treatment strategies for IFI (i.e. combination anti-fungal therapy)

 

 

Immunization Update for Immunosuppressed Patients

0180-0000-14-307-L01-P

Program Type: Knowledge-based

Acute Care Track

Wednesday, April 30, 2014

2:30-3:00 pm

 

Session Handout: www.ppag.org/23AM/eiland.pdf

 

Lea Eiland, PharmD., BCPS, FASHP

Clinical Professor and Associate Department Head of Pharmacy Practice

Auburn University Harrison School of Pharmacy, Auburn, Alabama

 

At the end of this session, participants will be able to:

1.        List example diseases and medications that cause immunosuppression

2.        Identify vaccines that are needed for hematopoietic stem cell transplant recipients

3.        Describe risks of administering vaccines to patients with immunosuppressed household contacts

 

 

Oncologic Emergencies

0180-0000-14-308-L01-P

Program Type: Knowledge-based

Critical Care Track

Wednesday, April 30, 2014

1:30-2:00 pm

 

Session Handout: www.ppag.org/23AM/steinwedel.pdf

 

Erin Steinwedel, PharmD

Clinical specialist, Oncology

Arnold Palmer Hospital for Children, Orlando, Florida

 

At the end of this session, participants will be able to:

1.        Identify risk factors and complications of hyperleukocytosis and tumor lysis syndrome.

2.        Formulate an appropriate laboratory monitoring plan for patients with tumor lysis syndrome.

3.        Recommend a treatment plan for a patient with tumor lysis syndrome.

 

 

Novel Treatment Options for Chronic Graft-Versus-Host Disease in the Critical Care Setting

0180-0000-14-309-L01-P

Program Type: Knowledge-based

Critical Care Track

Wednesday, April 30, 2014

2:00-2:30 pm

 

Session Handout: www.ppag.org/23AM/barnett.pdf

 

Alina Barnett, PharmD, BCPS

Clinical Pharmacist

UCSF Benioff Children's Hospital, San Francisco, California

 

At the end of this session, participants will be able to:

1.        Review immunology, pathology and clinical manifestations of chronic graft-versus-host disease.

2.        Compare novel treatment options for chronic graft-versus-host disease.

3.        Discuss potential medication related infectious complications.

 

 

Hemophagocytic Lymphohistiocytosis

0180-0000-14-310-L01-P

Program Type: Knowledge-based

Critical Care Track

Wednesday, April 30, 2014

2:30-3:00 pm

 

Session Handout: www.ppag.org/23AM/price.pdf

 

Jessica Price, PharmD

Clinical Specialist, Hematology/Oncology

Children's Hospital of The King's Daughters (CHKD), Norfolk, Virginia

 

At the end of this session, participants will be able to:

1.        Understand the pathophysiology of HLH.

2.        List the diagnostic guidelines for HLH.

3.        Understand how to treat a patient with HLH using current therapeutic guidelines.

 

 

Chemotherapy within an Electronic Health Record - Safety First

0180-0000-14-311-L04-P

Program Type: Knowledge-based

Acute Care Track

Wednesday, April 30, 2014

3:05-4:35 pm

 

Session Handout: www.ppag.org/23AM/baker-mcdaniel.pdf

www.ppag.org/23AM/clark.pdf

 

Don Baker, PharmD, MBA

Clinical Decision Support Officer

St. Jude Children's Research Hospital, Memphis, Tennessee

 

Ben McDaniel, PharmD

Medication Safety PGY2 Resident

St. Jude Children's Research Hospital, Memphis, Tennessee

 

Richard Clark, PharmD

St. Jude Children’s Research Hospital, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1.        Be able to name 2 different types of clinical decision support mechanisms

2.        Understand how both active and passive decision support play a role in enhancing medication safety within an electronic medical record system

3.        Describe how complex chemotherapy regimens can be safely ordered, dispensed, and administered using an electronic medical record system.

 

Veno-occlusive Disease

0180-0000-14-312-L01-P

Program Type: Knowledge-based

Critical Care Track

Wednesday, April 30, 2014

3:05-3:35 pm

 

Session Handout: www.ppag.org/23AM/held.pdf

 

Kristin Held, PharmD, BCOP

Clinical Specialist

Lehigh Valley Health Network, Allentown, Pennsylvania

 

At the end of this session, participants will be able to:

1.        Define veno-occlusive disease (VOD)

2.        Identify the risk factors associated with VOD

3.        Describe the clinical presentation of VOD

4.        Recommend appropriate prophylactic therapies for VOD

5.        Discuss management strategies available for and outcomes in managing VOD

 

Anthracycline-Induced Heart Disease

0180-0000-14-313-L01-P

Program Type: Knowledge-based

Critical Care Track

Wednesday, April 30, 2014

3:35-4:05 pm

 

Session Handout: www.ppag.org/23AM/ward.pdf

 

Deborah Ward, PharmD, BCOP, BCPS

Clinical pharmacy specialist

St Jude Children's Research Hospital, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1.        Define the underlying pathophysiology of anthracyline-induced cardiac toxicity

2.        Identify patient specific risk factors for both acute and delayed cardiac toxicity

3.        Describe the management of acute anthracycline-induced cardiac toxicity

 

 

Superior Vena Cava (SVC) Syndrome: Understanding Causes, Symptoms, and Treatment

0180-0000-14-314-L01-P

Program Type: Knowledge-based

Critical Care Track

Wednesday, April 30, 2014

4:05-4:35 pm

 

Session Handout: www.ppag.org/23AM/saylor.pdf

 

Matthew Saylor, PharmD, BCOP

Clinical pharmacy specialist, hematology/oncology

Novant Health - Presbyterian Medical Center, Charlotte, North Carolina

 

At the end of this session, participants will be able to:

1.        To demonstrate understanding of SVC syndrome.

2.        To determine appropriate treatment for SVC syndrome.

3.        To extrapolate guidelines to fit their respective patient population.

 

 

Critical Care for Children with Cancer: The St. Jude Experience

Program Type: Knowledge-based

0180-0000-14-315-L04-P

Keynote Address

Wednesday, April 30, 2014

4:40-5:40 pm

 

Session Handout: www.ppag.org/23AM/morrison.pdf

 

R. Ray Morrison, M.D.

Critical Care Division Chief

St. Jude Children's Research Hospital, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1.        Recognize common causes of respiratory failure in children who have cancer or who have undergone hematopoietic stem cell transplantation.

2.        Identify risks associated with other end-organ dysfunction in pediatric cancer patients who experience respiratory failure.

3.        Appreciate the medical and pharmaceutical complexity inherent in caring for critically ill children with cancer.

 

 

 

Thursday, May 1, 2014

 

Defibrotide for the prevention of hepatic veno-occlusive disease

0180-0000-14-316-L01-P

Program Type: Knowledge-based

Clinical Pearl

Thursday, May 1, 2014

8:00-8:20 am

 

Session Handout: www.ppag.org/23AM/mccabe.pdf

 

Tara McCabe, PharmD

Clinical pharmacy specialist, Hematology/Oncology

UF Health Shands Children's Hospital, Gainesville, Florida

 

At the end of this session, participants will be able to:

1.        Identify risk factors for pediatric hematopoietic stem cell transplant patients to develop hepatic veno-occlusive disease

2.        Compare and contrast the options for preventing hepatic veno-occlusive disease

3.        Analyze the literature regarding the use of defibrotide for prophylaxis of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant patients

 

 

Implementation of Vincristine Minibags in Pediatric Cancer Patients

0180-0000-14-317-L01-P

Program Type: Knowledge-based

Clinical Pearl

Thursday, May 1, 2014

8:20-8:40 am

 

Session Handout: www.ppag.org/23AM/robertson.pdf

 

Jennifer Robertson, PharmD, BCPS

Medication Use Policy Coordinator

St. Jude Children's Research Hospital, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1.        Describe the dangers of dispensing vinca alkaloids in a syringe.

2.        Identify issues for consideration when implementing vinca alkaloid minibags in pediatric cancer patients.

3.        Describe how vinca alkaloid minibags were implemented in one institution.

 

 

Safe Handling of Oral Chemotherapy

0180-0000-14-318-L01-P

Program Type: Knowledge-based

Clinical Pearl

Thursday, May 1, 2014

8:40-9:00 am

 

Session Handout: www.ppag.org/23AM/devine.pdf

 

Meghan Devine, PharmD

Clinical pharmacy specialist, hematology and oncology

 

Carolina's HealthCare System/ Levine Children's Hospital, Charlotte, North Carolina

 

At the end of this session, participants will be able to:

1.        List current guidelines and policies for safe handling of oral chemotherapeutic agents

2.        Describe the risks associated with chemotherapeutic exposure

3.        Discuss safe handling practices for health care providers and patients/caregivers

 

 

Forecasting the Future: Novel Treatment Strategies in Sickle Cell Disease

0180-0000-14-319-L01-P

Program Type: Knowledge-based

Acute Care Track

Thursday, May 1, 2014

9:00-9:45 am

 

Session Handout: www.ppag.org/23AM/elder.pdf

 

Joshua Elder, PharmD, BCPS

Hematology/Oncology/Stem Cell Transplant Clinical Specialist

Kosair Children's Hospital, Louisville, Kentucky

 

At the end of this session, participants will be able to:

1.        Identify novel therapeutic agents to treat sickle cell disease.

2.        Describe pharmacogenomic implications in the management of sickle cell disease.

3.        Discuss curative therapeutic modalities in sickle cell disease.

 

 

What's Happenin' in Hemophilia

0180-0000-14-320-L01-P

Program Type: Knowledge-based

Acute Care Track

Thursday, May 1, 2014

9:45-10:30 am

 

Session Handout: www.ppag.org/23AM/trinkman.pdf

 

Heidi Trinkman, PharmD

Clinical Specialist, Hematology/Oncology

Cook Children's Medical Center, Fort Worth, Texas

 

At the end of this session, participants will be able to:

1.        Describe the differences in the factor products available for the treatment of acute bleeds in patients with hemophilia.

2.        List different treatment approaches available for patients with inhibitors.

3.        Explain the technological advances in the field of hemophilia treatment and how they are changing the future of therapy.

 

 

Chemotherapy-induced Fever and Neutropenia

0180-0000-14-321-L01-P

Program Type: Knowledge-based

Critical Care Track

Thursday, May 1, 2014

9:00-9:45 am

 

Session Handout: www.ppag.org/23AM/bruce.pdf

 

Katie Bruce, PharmD

Clinical Pharmacist, Stem Cell Transplant

Vanderbilt Children's, Nashville, Tennessee

 

At the end of this session, participants will be able to:

1.        Review risk associated with chemotherapy induced neutropenia

2.        Review colony-stimulating factors used to shorten neutropenic period.

3.        Evaluate literature available for empiric treatment of fever in a neutropenic patient.

 

 

Typhlitis (neutropenic enterocolitis)

0180-0000-14-322-L01-P

Program Type: Knowledge-based

Critical Care Track

Thursday, May 1, 2014

9:45-10:30 am

 

Session Handout: www.ppag.org/23AM/rohatgi.pdf

 

Radha Rohatgi, PharmD, BCOP

Clinical specialist, Hematology

Children's National Health Systems, Washington, D.C.

 

At the end of this session, participants will be able to:

1.        Assess risks for typhlitis in pediatric patients receiving chemotherapy

2.        Describe the clinical manifestations and diagnosis of typhlitis

3.        Outline a plan utilizing therapeutic strategies and pharmacologic agents for the treatment of typhlitis.

 

Palliative Care Workshop

0180-0000-14-323-L01-P

Program Type: Knowledge-based

Acute Care Track

Thursday, May 1, 2014

10:35-12:05 pm

 

Session Handout: www.ppag.org/23AM/hagemann.pdf

 

Tracy Hagemann, PharmD, FCCP, FPPAG

Professor of Pharmacy and Director of Clinical Affairs

University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma

 

At the end of this session, participants will be able to:

1.        Define palliative care practices in pediatric oncology, including end of life care.

2.        Identify categories of palliative care pharmacotherapy.

3.        Identify methods to provide palliative care pharmacotherapy to pediatric hematology and oncology patients.

4.        Describe the role of the pediatric pharmacist in palliative care activities.

 

 

Update on Chemotherapy Drug Shortages

0180-0000-14-324-L01-P

Program Type: Knowledge-based

Critical Care Track

Thursday, May 1, 2014

10:35-11:05 am

 

Session Handout: www.ppag.org/23AM/hall-snyder-kassa.pdf

 

Laura Hall, PharmD

Clinical pharmacist, Oncology

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

 

Brandy Snyder, PharmD, BCOP, CPP

Clinical Specialist, Hematology/Oncology

Wake Forest Baptist Health, Winston-Salem, North Carolina

 

Mekdese Kassa, PharmD, BCOP

Oncology Pharmacy Operations and Clinical Manager

Alvin & Lois Lapidus Cancer Institute and The Herman and Walter Samuelson Children’s Hospital

Life Bridge Health, Baltimore, Maryland

 

At the end of this session, participants will be able to:

1.        Define causes of drug shortages and chemotherapy drugs affected

2.        Discuss impact of drug shortages on patient care

3.        Identify policies to address chemotherapy drug shortages

4.        Discuss Children’s Oncology Group’s (COG) recommendations for managing shortages

5.        Describe strategies for prevention and management for drug shortages

6.        Breakout session: Discuss chemotherapy drug shortages among participants and learn to apply COG recommendations and strategies

 

 

Navigating Asparaginase in Leukemia

0180-0000-14-325-L01-P

Program Type: Knowledge-based

Symposium

Thursday, May 1, 2014

12:05-1:30 pm

 

Session Handout: www.ppag.org/23AM/parsons_symposium.pdf

 

Kerry Parsons, PharmD, BCOP

Clinical Pharmacist, Oncology

Children's of Alabama, Birmingham, Alabama

 

At the end of this session, participants will be able to:

1.        Discuss integration of asparaginase preparations in treatment of acute lymphoblastic leukemia.

2.        Compare asparaginase products including pharmacology, dosing, administration, and toxicities.

3.        Provide insights into prevention and management of asparaginase-related toxicities.

 

 

Voriconazole TDM review - challenging recommended dosing

0180-0000-14-326-L01-P

Program Type: Knowledge-based

General Session

Thursday, May 1, 2014

1:30-1:50 pm

 

Session Handout: www.ppag.org/23AM/stricherz.pdf

 

Melisa Stricherz, PharmD, BCOP

Clinical Pharmacist, BMT/Hematology/Oncology

University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota

 

At the end of this session, participants will be able to:

1.        Review Voriconazole PK

2.        Discuss the differences between children and adults

3.        Review Dosing and Therapeutic Drug Monitoring

4.        Discuss how to choose a starting dose

5.        Discuss when levels should be checked and understand the goals of therapy

6.        Understand how to adjust levels to achieve goals.

 

 

Posaconazole pharmacokinetics and therapeutic drug monitoring

0180-0000-14-327-L01-P

Program Type: Knowledge-based

General Session

Thursday, May 1, 2014

1:50-2:10 pm

 

Session Handout: www.ppag.org/23AM/scott.pdf

 

Jeff Scott, PharmD, BCPS

Clinical Pharmacy Specialist

St. Jude Children's Research Hospital, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1.        Describe the pharmacokinetics of posaconazole

2.        Assess barriers to absorption of posaconazole suspension

3.        Summarize posaconazole therapeutic drug monitoring

 

 

Therapeutic Drug Monitoring-Beta-lactams

0180-0000-14-328-L01-P

Program Type: Knowledge-based

General Session

Thursday, May 1, 2014

2:10-2:30 pm

 

Session Handout: www.ppag.org/23AM/cies.pdf

 

Jeffrey Cies, PharmD, MPH, BCPS-AQ ID

Clinical Pharmacist, Critical Care and Infectious Diseases

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania

 

At the end of this session, participants will be able to:

1.        Provide brief overview/background of rationale behind therapeutic drug monitoring with beta-lactams

2.        Discuss some recent evidence regarding therapeutic drug monitoring with beta-lactams

3.        Provide an update regarding therapeutic drug monitoring with beta-lactams

 

 

Pediatric Resident Panel: Tips from Trainees: Getting and Rocking a Pediatric Residency

Student Session

Thursday, May 1, 2014

2:35-3:35 pm

 

 

Katie Andricopulos, PharmD

PGY2

University of Kentucky HealthCare, Lexington, Kentucky

 

Cady Ploessl, PharmD, BCPS

PGY2

Children's Hospital of Georgia, Augusta, Georgia

 

Josh Heffren, PharmD

PGY2

Children's Hospital Colorado, Aurora, Colorado

 

Mary Babico, PharmD

PGY2

University of Arizona Diamond Children's Center, Tuscon, Arizona

 

Andrea McMunn, PharmD

PGY2

The Johns Hopkins Hospital, Baltimore, Maryland

 

 

At the end of this session, participants will be able to:

1.        Discuss reasons for choosing pediatric pharmacy as a specialty path

2.        Provide insights on how students can prepare for residency

3.        Discuss common mistakes that students and resident make

4.        Provide advice for obtaining a residency position

 

 

Friday, May 2, 2014

 

The Paradigm Shift in Pediatric Drug Use: Therapeutic Orphans No More

0180-0000-14-329-L01-P

Program Type: Knowledge-based

The Yaffe Award Lecture: Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics

Friday, May 2, 2014

8:00-9:00 am

 

Session Handout: www.ppag.org/23AM/burckart.pdf

 

Gilbert Burckart, PharmD

Associate Director for Pediatrics

Office of Clinical Pharmacology

Office of Translational Sciences, CDER

U.S. Food and Drug Administration

 

At the end of this session, participants will be able to:

1.        Discuss the present state of drug approvals for pediatric patients under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act

2.        List the therapeutic areas in which the most failed pediatric trails have occurred, and the study design considerations for failed pediatric trials

3.        Describe the steps that are necessary for a pediatric practitioner to become trained in pediatric drug research and join a national network of pediatric trials

 

 

Effect of a Pharmacist-Led Quality Improvement Initiative in a Pediatric Oncology Setting

0180-0000-14-330-L04-P

Program Type: Knowledge-based

Lexi-Comp Best Practice Award

Friday, May 2, 2014

9:05-9:15 am

 

Session Handout: www.ppag.org/23AM/elder_bestpractice.pdf

 

Joshua J. Elder, PharmD, BCPS

Clinical Specialist - Hematology/Oncology/Stem Cell Transplant

Kosair Children’s Hospital, Louisville, Kentucky

 

At the end of this session, participants will be able to:

1.        Describe the initiation of two pharmacist-led committees as a quality improvement initiative in a pediatric oncology setting

2.      Discuss the mission of the Chemotherapy Safety Committee and Children’s Oncology Group (COG) Committee

3.      Review outcomes of Chemotherapy Safety Committee and COG Committee

 

 

Reduction of Broad-Spectrum Anti-microbial Use in a Tertiary Children’s Hospital after Anti-microbial Stewardship Program Guideline Implementation

0180-0000-14-331-L04-P

Lexi-Comp Best Practice Award

Friday, May 2, 2014

9:20-9:35 am

 

Session Handout: www.ppag.org/23AM/lee.pdf

 

Kelley Lee, PharmD, BCPS

Le Bonheur Children’s, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1. Describe the two core strategies recommended for antimicrobial stewardship programs.

2.     Understand how antibiotic guidelines can be implemented in a pediatric critical care unit.

3.     Identify methods for decreasing broad-spectrum antibiotic use.

 

 

Medication Safety: Behaviors and Perceptions Among Parents and Guardians

0180-0000-14-332-L04-P

Program Type: Knowledge-based

Platform Presentation

Friday, May 2, 2014

9:35-9:45 am

 

Session Handout: www.ppag.org/23AM/matson.pdf

 

Kelly L. Matson, BSNutr, Pharm.D.

Associate Professor

University of Rhode Island, Kingston, Rhode Island

 

At the end of this session, participants will be able to:

1.        Review current trends and statistics of non-medical use of prescription medications among adolescents

2.        Summarize parents’ behaviors and perceptions of proper prescription medication use, storage and disposal 

3.       Discuss the pharmacist’s role in educating parents about proper medication use and dangers of misuse

 

 

Aminoglycoside pharmacokinetic parameter in infants with cystic fibrosis

0180-0000-14-333-L01-P

Platform Presentation

Friday, May 2, 2014

9:50-10:05 am

 

Session Handout: www.ppag.org/23AM/walleser_platform.pdf

 

Nathan Walleser, PharmD

Nationwide Children’s Hospital, Columbus, Ohio

 

At the end of this session, participants will be able to:

1.        Identify known pharmacokinetic changes in patients with cystic fibrosis

2.        Describe aminoglycoside pharmacokinetic parameters in infants with cystic fibrosis

3.        Recommend an empiric aminoglycoside dose most likely to achieve goal pharmacokinetic parameters in infants with cystic fibrosis

 

 

 

Pediatric Pharmacy: Look to the Future

0180-0000-14-334-L04-P

The Helms Award Lecture: The Richard A. Helms Award of Excellence in Pediatric Pharmacy Practice

Friday, May 2, 2014

1:35-2:35 pm

 

Session Handout: www.ppag.org/23AM/luedtke.pdf

 

Sherry Luedtke, PharmD

Associate Professor, Pharmacy Practice

Texas Tech University School of Pharmacy, Amarillo, Texas

 

 

At the end of this session, participants will be able to:

1.        Describe the changing face of pediatric pharmacy and its leadership.

2.        Identify personal contributions which can impact the future of pediatric pharmacy.

3.        Inspire future leaders of pediatric pharmacy.

 

 

Communicating with Pediatric Patients and Their Caregivers

0180-0000-14-335-L04-P

Program Type: Knowledge-based

Student Session

Friday, May 2, 2014

2:40-3:40 pm

 

Session Handout: www.ppag.org/23AM/schmidt.pdf

 

Deidra Schmidt, PharmD

Clinical pharmacist, Ambulatory Care

Children's of Alabama, Birmingham, Alabama

 

At the end of this session, participants will be able to:

1.        Describe how communication strategies differ according to a child’s developmental stage/age

2.        Identify four methods to improve communication with pediatric patients

3.        Describe strategies for improving medication compliance in the pediatric patient population

 

 

Live at Monroe Carell Jr. Children’s Hospital at Vanderbilt

0180-0000-14-336-L04-P

Program Type: Knowledge-based

Hospital Tour

Friday, May 2, 2014

3:45-5:45 pm

 

At the end of this session, participants will be able to:

1.        Explain the pharmacy practice model at MCJCHV

2.        Describe clinical pharmacy services provided at MCJCHV

3.        List technology utilized at MCJCHV through the medication use process

4.        Describe implementation of innovative IV robotic technology systems for sterile product preparation

 

 

 

Saturday, May 3, 2014

 

Updates in Acute Otitis Media

0180-0000-14-337-L01-P

Program Type: Knowledge-based

Clinical Pearl

Saturday, May 3, 2014

8:00-8:20 am

 

Session Handout: www.ppag.org/23AM/lucas.pdf

 

Sarah Scarpace Lucas, PharmD, BCPS, FCSHP

Clinical Pharmacist

UCSF Benioff Children's Hospital, San Francisco, California

 

At the end of this session, participants will be able to:

1.        Review pathophysiology, risk factors and diagnosis of Acute Otitis Media

2.        Discuss the therapy management changes in the 2013 Acute Otitis Media Guidelines

3.        Describe therapeutic treatment options for recurrent Otitis Media

4.        Apply guidelines to therapy for selected patient cases

 

 

Paving the Way to Excellent Patient Care Through Change

0180-0000-14-338-L04-P

Program Type: Knowledge-based

Clinical Pearl

Saturday, May 3, 2014

8:20-8:40 am

 

Session Handout: www.ppag.org/23AM/cooper.pdf

 

Mary Temple-Cooper, MS, PharmD, BS, BCPS

Clinical Specialist

Hillcrest Hospital, Cleveland Clinic, Mayfield Heights, Ohio

 

 

At the end of this session, participants will be able to:

1.        Discuss some of the changes at Hillcrest Hospital

2.        Discuss some notable successes that came with change

3.        Delineate key steps to facilitate change

4.        Provide options to manage barriers and impacts of change on your staff

 

 

Diaper Dermatitis: A Most Irritating Issue

0180-0000-14-339-L01-P

Program Type: Knowledge-based

Clinical Pearl

Saturday, May 3, 2014

8:40-9:00 am

 

Session Handout: www.ppag.org/23AM/hoffmaster.pdf

 

Holly Hoffmaster, PharmD, BCPS

Clinical Pharmacist

Cleveland Clinic, Cleveland, Ohio

 

At the end of this session, participants will be able to:

1.        Identify common types of diaper dermatitis

2.        List risk factors that lead to diaper dermatitis

3.        Describe methods of prevention and treatment of diaper dermatitis

4.        Recognize when to consider escalating care

 

 

Updates in Cystic Fibrosis: A review of the literature and impact on care

0180-0000-14-340-L01-P

Program Type: Knowledge-based

General Session

Saturday, May 3, 2014

9:00-9:30 am

 

Session Handout: www.ppag.org/23AM/john.pdf

 

Bob John, PharmD, BCPS

Clinical Assistant Professor of Pediatric Pharmacotherapy

The University of Oklahoma College of Pharmacy-Tulsa, Tulsa, Oklahoma

 

At the end of this session, participants will be able to:

1.        Evaluate literature published in the last year pertaining to the pharmacotherapy of cystic fibrosis

2.        Describe the impact of recent data on the current care of patients with cystic fibrosis

 

Asthma Genotypes and Phenotypes and Endotypes, OH MY!

0180-0000-14-341-L01-P

Program Type: Knowledge-based

General Session

Saturday, May 3, 2014

9:30-10:00 am

 

Session Handout: www.ppag.org/23AM/lubsch.pdf

 

Lisa Lubsch, PharmD, AE-C

Clinical Associate Professor

Southern Illinois University-Edwardsville School of Pharmacy/Cardinal Glennon Children’s

Edwardsville, Illinois

 

At the end of this session, participants will be able to:

1.        Define genotype, phenotype, and endotype and differentiate each in relation to asthma

2.        Review current and theoretical classifications of asthma

3.        Discuss how phenotype and endotype classifications may predict asthma treatment response

 

 

Nephrotic Syndrome - the Ins and Outs

0180-0000-14-342-L01-P

Program Type: Knowledge-based

Acute Care Track

Saturday, May 3, 2014

10:05-10:50 am

 

Session Handout: www.ppag.org/23AM/roehrs.pdf

 

Stacy Roehrs, B.S. Pharm, PharmD

Clinical Coordinator

Dayton Children's, Dayton, Ohio

 

At the end of this session, participants will be able to:

1.        Describe the presenting symptoms of nephrotic syndrome.

2.        List the usual treatments and management for nephrotic syndrome.

3.        List the treatments for steroid resistant nephrotic syndrome.

 

 

Updates in Pediatric Chronic Renal Failure: What's New?

0180-0000-14-343-L01-P

Program Type: Knowledge-based

Acute Care Track

Saturday, May 3, 2014

10:50-11:35 pm

 

Session Handout: www.ppag.org/23AM/gill.pdf

 

Hardeep Gill, PharmD, BCPS

Clinical Pharmacist

UCSF Benioff Children's Hospital, San Francisco, California

 

At the end of this session, participants will be able to:

1.        Evaluate the 2012-2013 KDIGO guidelines on children with CKD in regards to lipid management, BP control, and anemia & discuss the US KDOQI stance on these updates

2.        Review the methods utilized in calculating eGFR in pediatrics with CKD. What is the role of newer eGFR formulas in pediatrics?

3.        Compare and contrast the 2012 ISPD guidelines on treatment of peritonitis in PD & highlight the major differences from the 2000 guidelines.

 

 

IV Robotics

0180-0000-14-344-L04-P

Program Type: Knowledge-based

Professional Development

Saturday, May 3, 2014

10:05-11:35 am

 

Session Handout: www.ppag.org/23AM/carberry-humphreys.pdf

 

Beth Carberry, RPh, MBA, PLA

Director of Pharmacy

All Children's Hospital, St. Petersburg, Florida

 

Elizabeth Humphreys, PharmD

Director of Pharmacy

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

 

At the end of this session, participants will be able to:

1.        Recognize the utility of IV robotics in a pediatric setting

2.        Understand the decision process for selection of IV robots

3.        Understand the implementation process for IV robotics

 

 

New Oral Anticoagulants for Venous Thromboembolism: The Search for the Ideal Anticoagulant for Pediatric Patients

0180-0000-14-345-L01-P

Program Type: Knowledge-based

Acute Care Track

Saturday, May 3, 2014

1:00-1:45 pm

 

Session Handout: www.ppag.org/23AM/hansen.pdf

 

Lizbeth Hansen, PharmD, BCPS

Clinical pharmacist

University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota

 

At the end of this session, participants will be able to:

1.        Understand the basics of developmental hemostasis and how they relate to existing options for pediatric anticoagulation

2.        Compare theoretical benefits and risks of new oral anticoagulants (OAC) to current options for long term treatment and prophylaxis of venous thromboembolism

3.        Discuss the clinical properties of each of the new OACs and the landmark adult trials that guide the use of them

4.        Apply the concepts of developmental hemostasis to determine the potential role of new OACs in pediatric anticoagulation

 

 

Clonidine making a comeback

0180-0000-14-346-L01-P

Program Type: Knowledge-based

Acute Care Track

Saturday, May 3, 2014

1:45-2:30 pm

 

Session Handout: www.ppag.org/23AM/johnson.pdf

 

Pete Johnson, PharmD, BCPS

Associate Professor of Pharmacy Practice

University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma

 

At the end of this session, participants will be able to:

1.        Describe the mechanism of action of alpha2 agonists in the management of pain.

2.        Identify the role of clonidine for drug withdrawal, pain management, and opioid tolerance in children.

3.        Provide recommendations for initial dosing and tapering of clonidine.

 

 

Non-Traditional PGY1 Residency Program

0180-0000-14-347-L04-P

Program Type: Knowledge-based

Professional Development

Saturday, May 3, 2014

1:00-2:30 pm

 

Session Handout: www.ppag.org/23AM/potts-grisso.pdf

 

Amy Potts, PharmD, BCPS

Assistant Director

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

 

Alison Grisso, PharmD

Clinical Pharmacist

Residency Program Director

Monroe Carell Jr, Children's Hospital at Vanderbilt, Nashville, Tennessee

 

At the end of this session, participants will be able to:

1.        Recognize benefits and barriers to implementing a non-traditional residency

2.        Develop strategies to achieve administrative and staff 'buy-in'

3.        Understand the relevance of a non-traditional residency.

 

 

Drug Shortages-The Perverse Effects on Pediatric Patient Care

0180-0000-14-348-L04-P

Program Type: Knowledge-based

Keynote Address

Saturday, May 3, 2014

2:35-3:35 pm

 

Session Handout: www.ppag.org/23AM/vaneeckhout.pdf

 

John VanEeckhout, PharmD

Paventia Health

Former Vice President of Clinical Services for Children’s Hospital Association

 

At the end of this session, participants will be able to:

1.        Discuss the recent trends of drug shortages.

2.        Describe how drug shortages affect pediatric care provision, safety and treatment outcomes.

3.        Discuss the impact of drug shortages on pediatrics hospitals procurement staffs and financial impact on the pharmacy drug costs.

4.        Discuss current status of activities to reduce shortages

 

 

 

Sunday, May 4, 2014

 

 

Proton Pump Inhibitors in Infants

0180-0000-14-349-L01-P

Program Type: Knowledge-based

Clinical Pearl

Sunday, May 4, 2014

7:00-7:10 am

 

Session Handout: www.ppag.org/23AM/shelton.pdf

 

Chasity Shelton, PharmD, BCPS, BCNSP

Assistant Professor

The University of Tennessee Health Science Center, Memphis, Tennessee

 

At the end of this session, participants will be able to:

1.        Identify the most commonly used proton pump inhibitors in the neonatal population.

2.        List adverse effects associated with acid suppressive therapy in the neonatal intensive care unit population.

3.        Recommend appropriate use of proton pump inhibitors in the neonatal population.

 

 

Subcutaneous IVIG

0180-0000-14-350-L01-P

Program Type: Knowledge-based

Clinical Pearl

Sunday, May 4, 2014

7:10-7:20 am

 

Session Handout: www.ppag.org/23AM/klein.pdf

www.ppag.org/23AM/klein_handout.pdf

 

Kristin Klein, PharmD, FPPAG

Clinical pharmacist specialist

University of Michigan, Ann Arbor, Michigan

 

At the end of this session, participants will be able to:

1.        Compare and contrast the differences in dosing, interval, and infusion time of subcutaneous vs. intravenous immune globulin

2.        List 3 advantages of subcutaneous administration of immune globulin when compared to intravenous administration of immune globulin

3.        Compare and contrast the differences in associated costs between subcutaneous and intravenous immune globulin

 

 

Uses for the Sunlight Vitamin in Pediatrics

0180-0000-14-351-L01-P

Program Type: Knowledge-based

Clinical Pearl

Sunday, May 4, 2014

7:20-7:30 am

 

Session Handout: www.ppag.org/23AM/tobison.pdf

 

Jennifer Tobison, PharmD

Outpatient clinical specialist

Peyton Manning Children's Hospital at St. Vincent, Indianapolis, Indiana

 

At the end of this session, participants will be able to:

1.        Recite recommended target levels for vitamin D

2.        Identify patients at high risk for vitamin D insufficiency or deficiency

3.        List current recommendations for vitamin D supplementation in the pediatric population

 

 

Inflammatory Bowel Disease

0180-0000-14-352-L01-P

Program Type: Knowledge-based

Acute Care Track

Sunday, May 4, 2014

7:30-8:15 am

 

Session Handout: www.ppag.org/23AM/gervase.pdf

 

Melissa Gervase, PharmD, AE-C

Clinical Pharmacist

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

 

At the end of this session, participants will be able to:

1.        Understand the basic pathophysiology and clinical presentation of Inflammatory Bowel Disease (IBD), differentiating between Crohn’s and Ulcerative Colitis

2.        Discuss treatment goals for the management of pediatric IBD

3.        Understand how to select and appropriately monitor pharmacotherapy for a patient with IBD

 

 

Urea Cycle Disorders: The Role of the Pharmacist 

0180-0000-14-353-L01-P

Program Type: Knowledge-based

Acute Care Track

Sunday, May 4, 2014

8:15-9:00 am

 

Session Handout: www.ppag.org/23AM/fuller.pdf

 

Paige Fuller, PharmD, BCPS

Clinical Pharmacy Specialist

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

 

At the end of this session, participants will be able to:

1. Explain the pathophysiology of Urea Cycle Disorders (UCDs).

2.       Describe the acute initial medication management of UCDs.

3.       Discuss the medications used in the chronic treatment of UCDs.

 

The Pharmacist's Role in Preparing Children for the Transition to Adult Care

0180-0000-14-354-L04-P

Program Type: Knowledge-based

Professional Development

Sunday, May 4, 2014

7:30-8:15 am

 

Session Handout: www.ppag.org/23AM/condren.pdf

 

Michelle Condren, PharmD, AE-C, CDE

Associate Professor and Department Chair of Pharmacy Practice

University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma

 

At the end of this session, participants will be able to:

1.        Identify barriers to transitioning from adolescent to adult care that can impact health outcomes.

2.        Discuss potential pharmacist interventions that promote readiness for transition to adult care.

3.        Provide examples of pharmacist involvement that can facilitate transition to adult care within or outside the same institution.

 

 

Sharing Lessons Learned Through My Health Care Journey

0180-0000-14-355-L04-P

Program Type: Knowledge-based

Professional Development

Sunday, May 4, 2014

8:15-9:00 am

 

Session Handout: www.ppag.org/23AM/fiechtner.pdf

 

Helen Fiechtner, PharmD, FPPAG

Clinical Pharmacist

 

At the end of this session, participants will be able to:

1.        Discuss how the signs and symptoms of evolving immune / auto-immune / inflammatory / anti-inflammatory disorders can change over time which can affect appropriate and timely diagnosis.

2.        Discuss how immune / auto-immune / inflammatory / anti-inflammatory disorders can change the signs and symptoms of other diseases.

3.        Discuss how evolving immune / auto-immune / inflammatory / anti-inflammatory disorders can change medication adverse reactions.

4.        Explain the usefulness of a patient history and treatment information sheet for a medically complex patient.

 

 

Cerebral Palsy

0180-0000-14-356-L01-P

Program Type: Knowledge-based

Acute Care Track

Sunday, May 4, 2014

9:00-9:45 am

 

Session Handout: www.ppag.org/23AM/billings.pdf

 

Cassie Billings, B.S, PharmD

Clinical Pharmacy Specialist-Pediatrics

James and Connie Maynard Children's Hospital, Greenville, North Carolina

 

At the end of this session, participants will be able to:

1.        Discuss the benefits and risks of different treatment modalities for spasticity.

2.        Summarize options for the management of drooling in patients with cerebral palsy.

3.        Recognize patients who are at risk for osteopenia and design a therapeutic strategy for prevention.

 

 

Psychoactive Medications in Breastfeeding

0180-0000-14-357-L01-P

Program Type: Knowledge-based

Acute Care Track

Sunday, May 4, 2014

9:45-10:30 am

 

Session Handout: www.ppag.org/23AM/burkey.pdf

 

Betsy Walters Burkey, PharmD, BCPS

Clinical specialist

Fairview Hospital / Cleveland Clinic Children's Hospital, Cleveland, Ohio

 

At the end of this session, participants will be able to:

1.        Describe the new proposed FDA drug labeling changes for medications in regards to lactation

2.        Recognize which infants are at the highest risk for adverse effects when potentially exposed to a medication through breast milk

3.        Utilize LactMed to evaluate real-time available medication information when asked questions about a psychoactive medications in breast-feeding

 

 

Stepping out of practice into management

0180-0000-14-358-L04-P

Program Type: Knowledge-based

Professional Development

Sunday, May 4, 2014

9:00-10:30 am

 

Session Handout: www.ppag.org/23AM/denson-bobo-whitehill.pdf

 

Brenda Denson, PharmD

Investigational Studies Pharmacist

Childrens of Alabama, Birmingham, Alabama

 

Kelly Bobo, PharmD, BCPS

Clinical Manager

Le Bonheur Children's Hospital, Memphis, Tennessee

 

Jordan Whitehill,PharmD, BCPS

Clinical Manager

Children’s Medical Center Dallas, Dallas, Texas

 

At the end of this session, participants will be able to:

1.        Describe the shortage of trained pharmacy leaders in hospital and other practice settings

2.        Outline available training programs for pharmacy leadership development

3.        Construct a decision tree for career path changes including pros, cons, challenges, and work-life balance

4.        Review things you never thought you would need or want to know related to management

 

 

Ketogenic Diet Protocols and Resources

0180-0000-14-359-L01-P

Program Type: Knowledge-based

General Session

Sunday, May 4, 2014

10:45-11:05 am

 

Session Handout: www.ppag.org/23AM/bogenschutz.pdf

 

Monica Bogenschutz, PharmD, BCPS

Clinical pharmacist

American Family Children's Hospital/University of Wisconsin Hospital and Clinics, Madison, Wisconsin

 

At the end of this session, participants will be able to:

1.        Briefly review Ketogenic Diet Therapy and rationale for use

2.        Discuss stages of therapy initiation and pharmacist role

3.        Identify medication related resources

 

 

 

Acetaminophen-The Changing Times

0180-0000-14-360-L01-P

Program Type: Knowledge-based

General Session

Sunday, May 4, 2014

11:05-11:25 am

 

Session Handout: www.ppag.org/23AM/benefield.pdf

 

Emily Benefield, PharmD, BCPS

Clinical pharmacist

Primary Children's Hospital, Salt Lake City, Utah

 

At the end of this session, participants will be able to:

1.        Describe the FDA recommendations for the maximum daily acetaminophen dosage.

2.        Identify an area for potential adverse events associated with acetaminophen containing products.

3.        Develop a plan to minimize the risk for acetaminophen related adverse events for inpatient pharmacy services.

 

 

Propranolol for Infantile Hemangioma

0180-0000-14-361-L01-P

Program Type: Knowledge-based

General Session

Sunday, May 4, 2014

11:25-11:45 am

 

Session Handout: www.ppag.org/23AM/zuckerman.pdf

 

Andrea Zuckerman, PharmD

Clinical Pharmacist

Cleveland Clinic Children’s, Cleveland Ohio

 

At the end of this session, participants will be able to:

1.        Describe clinical features and pathogenesis of infantile hemangioma (IH)

2.        Identify characteristics of IH for which drug therapy may be indicated

3.        Compare and contrast efficacy and adverse effects of standard therapy and propranolol for treatment of IH

4.        Describe the available evidence for use of propranolol in IH and consensus statement recommendations.

 

 

Getting the Most Out of Your Day without Losing Your Mind

0180-0000-14-362-L04-P

Program Type: Knowledge-based

General Session

Sunday, May 4, 2014

11:45-12:45 am

 

Session Handout: www.ppag.org/23AM/moffett.pdf

 

Brady Moffett, PharmD, MPH

Clinical pharmacy specialist

Texas Children's Hospital, Houston, Texas

 

At the end of this session, participants will be able to:

1.        Understand strategies for achieving and maintaining personal productivity

2.        Identify strategies for completing large or complex projects

3.        Understand the psychology behind procrastination

 

Calendar of Events

Upcoming Webinars

On-Demand Programs

 

Fall Conference